Author Archive: Roy Zwahlen

Roy Zwahlen

Roy is a Manager of Intellectual Property and Technology Transfer policy at BIO and the main contributor for Patently Biotech. He is a lawyer by training, with a background in international and national politics. He grew up in the developing world and believes that innovation can and does solve many of the world’s problems. Because of this, his work focuses on creating a worldwide policy environment that fosters innovation in the biotechnology sector to prevent and cure diseases such as HIV, to increase crop yields to feed more people, and to decrease the harmful effects of industry on the environment. Roy spends his free time keeping up with his two kids, a wife that knows everything (no joke), and serving in his church and broader community. Learn more about Roy from his Linkedin Profile.

Latest Posts

GAO Report on Bayh-Dole: Leverage to Promote Commercialization of Federally-Funded Inventions

The General Accountability Office submitted its report to Congress today on the administration of the regulations found under the Bayh-Dole Act, the foundation of all federally-funded research in the United States and one of the key factors in the creation (and boom) of biotechnology as both a research field and industry in the 1980s. A little background on Bayh-Dole: Technological innovation is widely seen as responsible for much of the economic growth and increased standard Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Department of State: Foster Climate Change Solutions, Biodiversity, & Economic Development with IPR Protections

CropLife has recently published their newest video interview last week with Carrie LaCrosse, of the Office of Intellectual Property Enforcement at the U.S. Department of State. LaCrosse discusses the value of IP for agriculture, looking in particular at new plant varieties and how IP is part of the solution in addressing the issues of food security.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO CEO: Patient Groups Join Call for Data Protection

Biomedical innovation is not only key to our industry’s future, but more importantly, continued medical breakthroughs are vital to patients living with debilitating diseases and their families. Without ongoing progress in our industry, patients of today and tomorrow have limited hope for future cures and therapies.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: ,

For July 4: Let’s Thank the Inventors

My hope for America this July 4? I hope, in 100 years, the response time to human and environmental suffering will be immediate. Until that day arrives (thanks to scientific breakthroughs funded by individual citizens) — let’s thank our scientists, investors, and inventors who work and play around us.

Finally, let’s also thank the founding fathers for knowing America’s innovative potential without seeing it for themselves.

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Twitter Twang: July 1st

Twitter Twang: July 1st

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: